Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced Tuesday positive top-line data from the Phase 3 CAHtalyst Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
The Phase 3 study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant percent reduction in daily glucocorticoid (GC) dose versus placebo while maintaining androgen control.
The study also met important key secondary endpoints, with a statistically significant decrease in androstenedione at Week 4 versus placebo. At Week 24, approximately 63% of patients on crinecerfont achieved a reduction to a physiologic GC dose versus approximately 18% on placebo.
Crinecerfont was generally well tolerated. The most common adverse events during the double-blind, placebo-controlled period of the trial were fatigue, headache, and coronavirus infection. There were few serious adverse events, with none assessed as related to crinecerfont.
Neurocrine Biosciences Reaches Settlement On INGREZZA ANDA Litigation
European Markets Close On Firm Note On Rate Cut Hopes, AI Optimism
U.S. Service Sector Activity Unchanged In September
Eurozone Private Sector Maintains Expansion
Bay Street Headed For Positive Start
FTSE 100 Up Firmly In Positive Territory, Set To End Week On Strong Note
CAC 40 Roughly Flat As Investors Focus On Economic Data
